Liquidia reports Q3 EPS (4c), consensus (33c)

Reports Q3 revenue $54.34M, consensus $18.86M. Cash and cash equivalents totaled $157.5M as of September 30, compared to $176.5M as of December 31, 2024. Roger Jeffs, Liquidia’s (LQDA) CEO, said: “Our Q3 results demonstrate the continued momentum of YUTREPIA’s launch and the clear enthusiasm from both prescribers and patients. As of October 30 we have received more than 2,000 unique prescriptions and shipped to more than 1,500 patients, supported by over 600 prescribers nationwide. As our real-world evidence continues to grow and access broadens, we continue to believe in YUTREPIA’s potential to become the preferred inhaled prostacyclin to treat patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. With the strong foundation established in our first full quarter post-launch, we are well positioned to pursue sustained growth and continued profitability, while thoughtfully investing in programs to expand YUTREPIA’s therapeutic profile and advance L606 into pivotal trials.”